We are live on ! Find out more
AVDL

Avadel Pharmaceuticals
AVDL

Delisted

AVDL was delisted on the 11th of February, 2026.

Back to rankings

87 hedge funds and large institutions have $360M invested in Avadel Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 27 increasing their positions, 25 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 4

14% more capital invested

Capital invested by funds: $316M → $360M (+$44.6M)

4% more funds holding

Funds holding: 84 → 87 (+3)

8% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 25

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

97% less call options, than puts

Call options by funds: $37K | Put options by funds: $1.08M

Holders
87
Holders Change
+3
Holders Change %
+3.57%
% of All Funds
2.32%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
7
Increased
27
Reduced
25
Closed
4
Calls
$37K
Puts
$1.08M
Net Calls
-$1.05M
Net Calls Change
-$65K

Top Buyers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
+$17.8M
2
IHM
Iguana Healthcare Management
New York
+$4.25M
3
AC
Armistice Capital
New York
+$3.29M
4
GTC
Ghost Tree Capital
New York
+$2.94M
5
Morgan Stanley
Morgan Stanley
New York
+$2.21M

Top Sellers

Rank Fund Capital Flow
1
JGC
J. Goldman & Co
New York
-$6.2M
2
Millennium Management
Millennium Management
New York
-$5.83M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$4.96M
4
EA
Emerald Acquisition
Washington
-$3.53M
5
FPC
Falcon Point Capital
California
-$2.42M
Name Holding Trade Value Shares
Change 		Change in
Stake
ST
76
Spot Trading
Illinois
$36K -$53.6K -4,100 -59%
Creative Planning
77
Creative Planning
Kansas
$25K – – –
UBS Group
78
UBS Group
Switzerland
$23K -$21.7K -1,661 -47%
TRCT
79
Tower Research Capital (TRC)
New York
$20K +$12K +919 +127%
Barclays
80
Barclays
United Kingdom
$19K +$12.3K +938 +159%
Wells Fargo
81
Wells Fargo
California
$15K +$2.14K +164 +16%
LTFS
82
Ladenburg Thalmann Financial Services
Florida
$9K – – –
WA
83
WFG Advisors
Texas
$7K – – –
WC
84
Whitnell & Co
Illinois
$6K – – –
AG
85
Advisor Group
Arizona
$1K +$26 +2 +2%
Point72 Asset Management
86
Point72 Asset Management
Connecticut
– -$4.96M -461,839 Closed
BIM
87
Bogle Investment Management
Massachusetts
– -$1.97M -183,440 Closed
SCM
88
Stonepine Capital Management
Oregon
– -$1.38M -128,005 Closed
QSS
89
Quantitative Systematic Strategies
Florida
– -$261K -24,232 Closed
JP Morgan Chase
90
JP Morgan Chase
New York
– -$1.1K -84 -71%
1 2 3
4

AVDL Hedge Fund Activity: Q3 2016 in Review

87 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q3 2016, worth a combined $360M — up 14% from $316M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new AVDL positions and 4 closed out — a net gain of 3 holders — while 27 added to existing stakes and 25 trimmed.

The largest buyer was Perceptive Advisors, opening a new position worth an estimated $17.8M. The largest seller was J. Goldman & Co, cutting an estimated $6.2M.

  • 87 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q3 2016, up from 84 in Q2 2016.
  • Funds reported $360M of Avadel Pharmaceuticals stock for Q3 2016, up 14% quarter-over-quarter.
  • 7 funds opened new Avadel Pharmaceuticals positions in Q3 2016 and 4 closed out, a net change of +3 holders.
  • The largest Avadel Pharmaceuticals buyer in Q3 2016 was Perceptive Advisors, an estimated $17.8M added.
  • The largest Avadel Pharmaceuticals seller in Q3 2016 was J. Goldman & Co, an estimated $6.2M sold.

Based on aggregated 13F filings for Q3 2016.